Dimethyl Fumarate for Obstructive Sleep Apnea

Completed · Phase 2 · Has a placebo group

Conditions studied: Obstructive Sleep Apnea, OSA, Sleep Apnea

In brief

The overall purpose of this study is to determine whether the oral medication dimethyl fumarate is an effective treatment for obstructive sleep apnea in patients who are unable, unwilling, or uneager to use positive airway pressure therapy.

Key facts

Study ID

NCT02438137

Run by

University of Michigan

People needed

65

Starts

2015-05-01

Expected to finish

2016-05-01

Last updated by the study team

2017-05-31

Who can join

Age: 18 and older, up to 65. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Age of 18-65 years at screening;
• Diagnosis of OSA as confirmed by previous clinical sleep study (polysomnography, PSG);
• Refusal, inability, or high reluctance to use CPAP regularly for treatment of OSA, despite medical advice;
• Willingness to undergo repeat sleep study (PSG) and blood studies;
• Normal immune cell counts, as evidenced by complete blood count (CBC) done at screening

You may not qualify if…

• Regular use of CPAP within the last 2 months
• Physical, psychiatric or cognitive impairment that prevents informed consent, PSG, or reliable follow-up;
• Cardiac conditions that may increase sleep apnea severity (e.g., congestive heart failure or recent heart attack);
• Current successful treatment for obstructive or central sleep apnea, for example by CPAP, and patient agreement to continue with that treatment;
• History of surgical treatment for OSA within past 6 months, or subsequent to last PSG confirmation that OSA is present;
• Active nervous system diseases that may predispose subjects to OSA;
• Systemic autoimmune disease that could increase inflammation and influence apnea severity (such as rheumatoid arthritis or lupus);
• Pregnancy or breastfeeding;
• Use of immunotherapies or immunosuppressants, currently or within past 6 months;
• Anticipated initiation or dose change in tricyclic antidepressants, selective serotonin uptake inhibitors, or related compounds;
• Participants with a history of active, serious or persistent infections.
• Participants with recent surgery (within 3 months prior to screening), or anticipated surgery during the length of the study.
• Systemic steroid use within the last 2 months (does not include local steroid injections or intranasal steroid spray);
• Current diagnosis of cancer that is not considered to be cured or in remission by the treating physician, cancer treatment of any kind within the last 6 months prior to screening (chemo, radiation, surgery), or anticipated cancer treatment during the length of the study;
• History of a lymphoproliferative disorder (such as leukemia);
• History of Multiple Myeloma
• History of decreased immune cell counts per a blood test known as a CBC, specifically lymphocyte counts less than 1.2 K/μL at screening.
• Refusal to use at least one reliable method of birth control (for women of childbearing age)
• Newly diagnosed (within 2 months) OSA subjects who have an AHI > 30 and history of serious, recent, or unstable cardiovascular disease (including but not limited to recent MI, recent stroke/TIA, or unstable angina)
• Participants who report previous motor vehicle accidents or near-misses presumed to be due to excessive sleepiness while driving.
• Any other condition or treatment that in the opinion of the investigator could affect subject safety or study eligibility.

Where it is running

• University of Michigan — Ann Arbor, Michigan, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.